title: Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC).
abstract: People with severe mental illnesses, such as schizophrenia, depression or bipolar disorder, have worse physical health and reduced life expectancy compared to the general population. The excess cardiovascular mortality associated with schizophrenia and bipolar disorder is attributed in part to an increased risk of the modifiable coronary heart disease risk factors; obesity, smoking, diabetes, hypertension and dyslipidaemia. Antipsychotic medication and possibly other psychotropic medication like antidepressants can induce weight gain or worsen other metabolic cardiovascular risk factors. Patients may have limited access to general healthcare with less opportunity for cardiovascular risk screening and prevention than would be expected in a non-psychiatric population. The European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) published this statement with the aim of improving the care of patients suffering from severe mental illness. The intention is to initiate cooperation and shared care between the different healthcare professionals and to increase the awareness of psychiatrists and primary care physicians caring for patients with severe mental illness to screen and treat cardiovascular risk factors and diabetes.
authors.affiliation: University Psychiatric, Centre Catholic University, Leuven campus Kortenberg, Leuvensesteenweg 517, 3070 Kortenberg, Belgium. marc.de.hert@uc-kortenberg.be
authors.forename: M
authors.initials: M
authors.lastname: De Hert
authors.forename: J M
authors.initials: JM
authors.lastname: Dekker
authors.forename: D
authors.initials: D
authors.lastname: Wood
authors.forename: K G
authors.initials: KG
authors.lastname: Kahl
authors.forename: R I G
authors.initials: RI
authors.lastname: Holt
authors.forename: H-J
authors.initials: HJ
authors.lastname: Möller
mesh_terms: D001714:Bipolar Disorder / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D002423:Cause of Death; D015897:Comorbidity; D003430:Cross-Sectional Studies; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D003920:Diabetes Mellitus / Q000139:chemically induced / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D005500:Follow-Up Studies; D006801:Humans; D008403:Mass Screening; D009765:Obesity / Q000453:epidemiology; D017410:Practice Guidelines as Topic; D011618:Psychotic Disorders / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D012955:Societies, Medical
chemical_list: D011619:Psychotropic Drugs